January 17, 2018 / 9:00 PM / a year ago

BUZZ-Aurinia Pharmaceuticals: Gains as CEO talks up sale prospect

** Canadian drug developer’s shares U.S. listed shares up as much as 7.8 pct at $5.79 - touches more than two month high; Toronto-listed stock also up about 8 pct

** CEO says co is likely to be acquired assuming it generates positive data for its lead asset voclosporin next year, according to a story from Dealreporter (bit.ly/2DIWZh6)

** Sale is most likely to occur following results of late-stage trial of immunosuppressant drug, Voclosporin, for treatment of lupus nephritis, according to the report

** Including Wednesday’s gains, AUPH has risen 136 pct over the 12 months (Reporting by Uday Sampath in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below